McKesson 5-year return hits 34.23%, beating market by 22.21%
- McKesson achieved a 34.23% average annual return over the last five years
- The stock outperformed the market by 22.21% on an annualized basis
- A $100 investment made five years ago is now worth $431.70
- Current market capitalization stands at $102.91 billion

*this image is generated using AI for illustrative purposes only.
McKesson Corporation (NYSE: MCK) has produced an average annual return of 34.23% over the past five years, outperforming the broader market by 22.21% on an annualized basis.
Currently, McKesson holds a market capitalization of $102.91 billion. The stock price stood at $882.70 at the time of writing, reflecting significant value accumulation for long-term holders.
Long-term compounding impact
The performance data illustrates the power of compounded returns in equity investments. An investor who had bought $100 worth of MCK stock five years ago would see that investment valued at $431.70 today. This growth highlights how sustained annual returns can multiply initial capital significantly over a medium-term horizon.
Key performance metrics
| Metric | Value |
|---|---|
| Average Annual Return (5 Years) | 34.23% |
| Market Outperformance (Annualized) | 22.21% |
| Current Market Cap | $102.91 billion |
| Current Stock Price | $882.70 |
| Value of $100 Investment (5 Years) | $431.70 |
What the numbers show
The divergence between McKesson’s 34.23% average annual return and its 22.21% annualized outperformance against the market indicates that the benchmark index itself returned approximately 12.02% annually during this period. This suggests that while the broader market provided positive returns, McKesson’s specific performance contributed nearly triple the market’s rate, driving the substantial absolute gain from $100 to $431.70.
What specific operational drivers or acquisitions have primarily fueled McKesson's 34.23% average annual return over the last five years?
How might increasing regulatory scrutiny on pharmaceutical distribution and pricing impact McKesson's ability to sustain its current outperformance?
Given the $102.91 billion market cap, what valuation multiples is McKesson currently trading at compared to its historical averages and peers like Cardinal Health?































